Filing Details

Accession Number:
0001144204-12-026347
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-05-04 17:11:37
Reporting Period:
2012-05-02
Filing Date:
2012-05-04
Accepted Time:
2012-05-04 17:11:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1006281 Protalix Biotherapeutics Inc. PLX Biological Products, (No Disgnostic Substances) (2836) 650643773
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1385112 David Aviezer C/O Protalix Biotherapeutics, Inc.
2 Snunit St, Science Park, Pob 455
Carmiel L3 20100
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-05-02 326,267 $0.12 326,267 No 4 M Indirect By Trust
Common Stock Acquisiton 2012-05-02 123,733 $0.97 450,000 No 4 M Indirect By Trust
Common Stock Disposition 2012-05-02 450,000 $7.13 0 No 4 S Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect By Trust
No 4 M Indirect By Trust
No 4 S Indirect By Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2012-05-02 326,267 $0.00 326,267 $0.12
Common Stock Stock Options (Right to Buy) Disposition 2012-05-02 123,733 $0.00 123,733 $0.97
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-12-08 No 4 M Direct
853,563 2016-09-10 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
  3. All of the options listed in Table II have vested.
  4. Does not include (i) options to purchase 600,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018, (ii) options to purchase 100,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, and (iii) options to purchase 250,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.